# Luspatercept for CIA in AML

> **NCT07663864** · PHASE1,PHASE2 · RECRUITING · sponsor: **Guangdong Second Provincial General Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Chemotherapy-inducing Anemia

## Interventions

- **DRUG:** Luspatercept Injectable Product

## Key facts

- **NCT ID:** NCT07663864
- **Lead sponsor:** Guangdong Second Provincial General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663864, "Luspatercept for CIA in AML". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07663864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*